The DOI matches its Crossref record.
Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production
Abstract
Previous studies have suggested a central role for superantigen-induced immune responses in the pathogenesis of streptococcal toxic shock syndrome. The production of streptococcal superantigens by clinical group A streptococcal (GAS) isolates was studied, and the ability of plasma collected from patients with severe invasive GAS infections to neutralize the proliferative- and cytokine-inducing activities of these superantigens was investigated. Overnight culture supernatants from all GAS isolates obtained from patients with invasive disease were found to contain superantigenic activity, as evident from their ability to drive potent T cell proliferation, induce high production of cytokines, and stimulate T cells in a V β-specific manner. Twelve patients with severe invasive GAS infections, including 11 streptococcal toxic shock syndrome cases and one necrotizing fasciitis without shock, were treated with i.v. infusions of normal polyspecific Ig (IVIG). Plasma samples collected from each patient before and after IVIG administration were analyzed for their ability to neutralize the activity of streptococcal superantigens produced by the GAS isolate that caused their disease. In all IVIG-treated patients, the capacity to neutralize the superantigenic activity, produced by their respective GAS isolate or by purified streptococcal pyrogenic exotoxins, increased in plasma following IVIG administration. Of particular clinical relevance, post-IVIG plasma from each patient completely blocked cytokine production elicited by their respective GAS culture supernatants or by purified streptococcal pyrogenic exotoxins. This study shows that IVIG treatment confers in vivo inhibitory activity against a large array of streptococcal superantigens and suggests that IVIG may be useful in the treatment of severe invasive streptococcal infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Pathogenesis of Group A Streptococcal Infections
Cunningham, M. W. (2000) · Clinical Microbiology Reviews · doi:10.1128/cmr.13.3.470 · Cited by 2,261
Toxic Shock Syndrome and Bacterial Superantigens: An Update
McCormick, J. K., Yarwood, J. M., & Schlievert, P. M. (2001) · Annual Review of Microbiology · doi:10.1146/annurev.micro.55.1.77 · Cited by 785
Necrotizing Fasciitis: Current Concepts and Review of the Literature
Sarani, B., Strong, M., Pascual, J., & Schwab, W. C. (2009) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2008.10.032 · Cited by 594
Darenberg, J., Ihendyane, N., Sjolin, J., Aufwerber, E., Haidl, S., Follin, P., Andersson, J., Norrby-Teglund, A., & The Streptlg Study Group (2003) · Clinical Infectious Diseases · doi:10.1086/376630 · Cited by 573
Self-citationKaul, R., McGeer, A., Norrby‐Teglund, A., Kotb, M., Schwartz, B., O'Rourke, K., Talbot, J., Low, D. E., & The Canadian Streptococcal Study Group (1999) · Clinical Infectious Diseases · doi:10.1086/515199 · Cited by 544
Self-citationHakkarainen, T. W., Kopari, N. M., Pham, T. N., & Evans, H. L. (2014) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2014.06.001 · Cited by 460
Gram-positive toxic shock syndromes
Lappin, E., & Ferguson, A. J. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70066-0 · Cited by 433
Clinical uses of intravenous immunoglobulin
Jolles, S., Sewell, W. A. C., & Misbah, S. A. (2005) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2005.02834.x · Cited by 374
Superantigens: microbial agents that corrupt immunity
Llewelyn, M., & Cohen, J. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00222-0 · Cited by 327
ZIMBELMAN, J., PALMER, A., & TODD, J. (1999) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199912000-00014 · Cited by 322
Invasive Group A Streptococcal Disease: Epidemiology, Pathogenesis and Management
Steer, A. C., Lamagni, T., Curtis, N., & Carapetis, J. R. (2012) · Drugs · doi:10.2165/11634180-000000000-00000 · Cited by 273
Intravenous Immunoglobulin: An Update on the Clinical Use and Mechanisms of Action
NEGI, V.-S., ELLURU, S., SIBÉRIL, S., GRAFF-DUBOIS, S., MOUTHON, L., KAZATCHKINE, M. D., LACROIX-DESMAZES, S., BAYRY, J., & KAVERI, S. V. (2007) · Journal of Clinical Immunology · doi:10.1007/s10875-007-9088-9 · Cited by 271
Chatellier, S., Ihendyane, N., Kansal, R. G., Khambaty, F., Basma, H., Norrby-Teglund, A., Low, D. E., McGeer, A., & Kotb, M. (2000) · Infection and Immunity · doi:10.1128/iai.68.6.3523-3534.2000 · Cited by 269
Self-citationMadsen, M. B., Hjortrup, P. B., Hansen, M. B., Lange, T., Norrby-Teglund, A., Hyldegaard, O., & Perner, A. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4786-0 · Cited by 128
Self-citation
Metadata
- Authors
- Norrby-Teglund, A., Kaul, R., Low, D. E., McGeer, A., Newton, D. W., Andersson, J., Andersson, U., & Kotb, M.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1996-04
- Volume
- 156
- Issue
- 8
- Pages
- 3057-3064
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1550776512
- Cited by
- 182
- References
- 0
- FWCI
- 13.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.